These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 28516859)

  • 1. Recombinant esterase from Corynebacterium pseudotuberculosis in DNA and subunit recombinant vaccines partially protects mice against challenge.
    Brum AA; Rezende AFS; Brilhante FS; Collares T; Begnine K; Seixas FK; Collares TV; Dellagostin OA; Azevedo V; Santos A; Portela RW; Borsuk S
    J Med Microbiol; 2017 May; 66(5):635-642. PubMed ID: 28516859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Corynebacterium pseudotuberculosis recombinant proteins rCP09720 or rCP01850 with rPLD as immunogens in caseous lymphadenitis immunoprophylaxis.
    Silva MTO; Bezerra FSB; de Pinho RB; Begnini KR; Seixas FK; Collares T; Portela RD; Azevedo V; Dellagostin O; Borsuk S
    Vaccine; 2018 Jan; 36(1):74-83. PubMed ID: 29174312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Corynebacterium pseudotuberculosis cp09 mutant and cp40 recombinant protein partially protect mice against caseous lymphadenitis.
    Silva JW; Droppa-Almeida D; Borsuk S; Azevedo V; Portela RW; Miyoshi A; Rocha FS; Dorella FA; Vivas WL; Padilha FF; Hernández-Macedo ML; Lima-Verde IB
    BMC Vet Res; 2014 Dec; 10():965. PubMed ID: 25527190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Saponin-adjuvanted recombinant vaccines containing rCP00660, rCP09720 or rCP01850 proteins against Corynebacterium pseudotuberculosis infection in mice.
    Bezerra FSB; Silva MTO; Rezende AFS; Lopes AS; de Pinho RB; Seixas FK; Collares TV; Portela RWD; Azevedo VAC; Borsuk S
    Vaccine; 2021 Apr; 39(18):2568-2574. PubMed ID: 33814234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NanH and PknG putative virulence factors as a recombinant subunit immunogen against Corynebacterium pseudotuberculosis infection in mice.
    Thais de Oliveira Silva M; Barros de Pinho R; da Rocha Fonseca B; Silvestre Brilhante Bezerra F; Severo Sabedra Sousa F; Kommling Seixas F; Collares T; José Meyer Nascimento R; Wagner Portela R; Ariston Carvalho Azevedo V; Borsuk S
    Vaccine; 2020 Dec; 38(51):8099-8106. PubMed ID: 33190945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant CP40 from Corynebacterium pseudotuberculosis confers protection in mice after challenge with a virulent strain.
    Droppa-Almeida D; Vivas WL; Silva KK; Rezende AF; Simionatto S; Meyer R; Lima-Verde IB; Delagostin O; Borsuk S; Padilha FF
    Vaccine; 2016 Feb; 34(8):1091-6. PubMed ID: 26796140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peptide vaccines designed with the aid of immunoinformatic against Caseous Lymphadenitis promotes humoral and cellular response induction in mice.
    Droppa-Almeida D; da Silva GA; Gaspar LMDAC; Pereyra BBS; Nascimento RJM; Borsuk S; Franceschi E; Padilha FF
    PLoS One; 2021; 16(11):e0256864. PubMed ID: 34843474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An iron-acquisition-deficient mutant of Corynebacterium pseudotuberculosis efficiently protects mice against challenge.
    Ribeiro D; Rocha Fde S; Leite KM; Soares Sde C; Silva A; Portela RW; Meyer R; Miyoshi A; Oliveira SC; Azevedo V; Dorella FA
    Vet Res; 2014 Mar; 45(1):28. PubMed ID: 24597857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protection of sheep against caseous lymphadenitis by use of a single oral dose of live recombinant Corynebacterium pseudotuberculosis.
    Hodgson AL; Tachedjian M; Corner LA; Radford AJ
    Infect Immun; 1994 Dec; 62(12):5275-80. PubMed ID: 7960105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant M. bovis BCG expressing the PLD protein promotes survival in mice challenged with a C. pseudotuberculosis virulent strain.
    Leal KS; de Oliveira Silva MT; de Fátima Silva Rezende A; Bezerra FSB; Begnini K; Seixas F; Collares T; Dellagostin O; Portela RW; de Carvalho Azevedo VA; Borsuk S
    Vaccine; 2018 Jun; 36(25):3578-3583. PubMed ID: 29759378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel approach for an immunogen against Corynebacterium pseudotuberculosis infection: An Escherichia coli bacterin expressing phospholipase D.
    Barros de Pinho R; de Oliveira Silva MT; Brenner G; Dié Alves MS; Azevedo V; Dias Portela R; Borsuk S
    Microb Pathog; 2021 Feb; 151():104746. PubMed ID: 33485993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of an ovine caseous lymphadenitis vaccine formulated using a genetically inactive form of the Corynebacterium pseudotuberculosis phospholipase D.
    Hodgson AL; Carter K; Tachedjian M; Krywult J; Corner LA; McColl M; Cameron A
    Vaccine; 1999 Feb; 17(7-8):802-8. PubMed ID: 10067685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of new Corynebacterium pseudotuberculosis antigens by immunoscreening of gene expression library.
    Galvão CE; Fragoso SP; de Oliveira CE; Forner O; Pereira RRB; Soares CO; Rosinha GMS
    BMC Microbiol; 2017 Sep; 17(1):202. PubMed ID: 28934943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccination confers significant protection of sheep against infection with a virulent United Kingdom strain of Corynebacterium pseudotuberculosis.
    Fontaine MC; Baird G; Connor KM; Rudge K; Sales J; Donachie W
    Vaccine; 2006 Aug; 24(33-34):5986-96. PubMed ID: 16806606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The combination of Brazilian red propolis and recombinant protein rCP01850 in the immunoprophylaxis of Corynebacterium pseudotuberculosis infection in mice.
    Brilhante Bezerra FS; Silva Rezende AF; Oliveira Silva MT; Sena-Lopes Â; Roesch-Ely M; Pêgas Henriques JA; Padilha FF; Carvalho Azevedo VA; Dias Portela RW; Seixas FK; Collares TV; Savegnago L; Borsuk S
    Microb Pathog; 2020 Dec; 149():104354. PubMed ID: 32569789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Development of an ELISA test to detect antibodies in vaccinated sheep or infected Corynebacterium pseudotuberculosis].
    Solanet JJ; Malena R; Estein SM; Estevao Belchior S; Paolicchi FA
    Rev Argent Microbiol; 2011; 43(1):9-17. PubMed ID: 21491060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A description of genes of Corynebacterium pseudotuberculosis useful in diagnostics and vaccine applications.
    D'Afonseca V; Moraes PM; Dorella FA; Pacheco LG; Meyer R; Portela RW; Miyoshi A; Azevedo V
    Genet Mol Res; 2008 Mar; 7(1):252-60. PubMed ID: 18551390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Establishment of an objective endpoint in mice model for caseous lymphadenitis vaccine trials.
    de Oliveira Silva MT; de Pinho RB; Bezerra FSB; Campos VF; Azevedo V; Borsuk S
    Vet Microbiol; 2019 Mar; 230():86-89. PubMed ID: 30827410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunisation against ovine caseous lymphadenitis: efficacy of monocomponent Corynebacterium pseudotuberculosis toxoid vaccine and combined clostridial-corynebacterial vaccines.
    Eggleton DG; Doidge CV; Middleton HD; Minty DW
    Aust Vet J; 1991 Oct; 68(10):320-1. PubMed ID: 1755782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Humoral and cellular immune responses of a murine model against Corynebacterium pseudotuberculosis antigens.
    El-Enbaawy MI; Saad MM; Selim SA
    Egypt J Immunol; 2005; 12(2):13-9. PubMed ID: 17977206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.